Klarin D, Zhu QM, Emdin CA…Kaushik VK, et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet. 2017; 49(9):1392-1397.
Wellington S, Nag PP, Michalska K,, et al. A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat Chem Biol. 2017; 13(9):943-950.
Garvie CW, Fraley CV, Elowe NH, et al. Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. Protein Sci. 2016;25(11):2018-2027.
Yamada K, Park HM, Rigel DF, et al. Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol. 2016 Nov;12(11):896-898.
Fang C, D’Souza B, Thompson CF, et al. Single diastereomer of a macrolactam core binds specifically to myeloid cell leukemia 1 (MCL1). ACS Med Chem Lett. 2014;5(12):1308–1312.
Virendar Kaushik, Ph.D.
Virendar Kaushik is the director of discovery sciences within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, where he is also an institute scientist. His research unit consists of protein science, structural biology, biochemistry, and biophysics groups that seamlessly work together to identify, validate, and mechanistically characterize potential small molecule therapeutics, with the goal of bringing transformative medicines to patients across multiple therapeutic areas. His research team is expert in protein biochemistry and purification, in vitro assay development, fragment and structure-based drug design, high-throughput screening, and drug discovery. In addition, Kaushik works with Broad Institute faculty in leading a number of academic and industrial collaborations.
Before coming to the Broad in 2012, Kaushik was an investigator within the Cardiovascular and Metabolic Disease Area at the Novartis Institutes for Biomedical Research, Inc. (NIBRI). His focus was on developing and executing the biochemistry strategy for therapeutics projects, and leading cross-functional pre-clinical discovery project teams. Prior to NIBRI, Kaushik did research on metabolic diseases and obesity at Millennium Pharmaceuticals.
Kaushik currently serves as an adjunct assistant professor at Tufts University’s Friedman School of Nutrition Science and Policy. He received his B.A. in biology and M.A. in physiology from Boston University and his Ph.D. in nutritional biochemistry from Tufts University.
Contact Virendar Kaushik via email at email@example.com.